RIGL - Rigel Pharmaceuticals
IEX Last Trade
13.45
-0.100 -0.743%
Share volume: 100,019
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.55
-0.10
-0.74%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-03 | 2023-03-07 | 2023-05-02 | 2023-08-01 | 2023-11-07 | 2024-03-05 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 128.001 M | 115.609 M | 134.279 M | 123.612 M | 117.091 M | 115.324 M | 117.225 M | 126.519 M | |
| Current Assets | 120.521 M | 110.440 M | 115.903 M | 106.972 M | 100.925 M | 95.024 M | 99.266 M | 92.486 M | |
| Inventories | 6.218 M | 7.116 M | 9.118 M | 11.077 M | 10.782 M | 6.112 M | 5.522 M | 6.579 M | |
| Other Current Assets | 7.939 M | 6.157 M | 8.259 M | 7.867 M | 4.967 M | 3.015 M | 6.261 M | 8.845 M | |
| Short Term Investments | 7.939 M | 6.157 M | 8.259 M | 7.867 M | 4.967 M | 3.015 M | 6.261 M | 8.845 M | |
| Total Receivables | 17.198 M | 15.525 M | 40.320 M | 29.366 M | 20.819 M | 23.546 M | 30.550 M | 27.512 M | |
| Current Cash | 89.166 M | 81.642 M | 58.206 M | 58.662 M | 64.357 M | 62.351 M | 56.933 M | 49.550 M | |
| Total Non-current Assets | 7.480 M | 5.169 M | 18.376 M | 16.640 M | 16.166 M | 20.300 M | 17.959 M | 34.033 M | |
| Property Plant Equipment | 1.832 M | 1.694 M | 857.000 K | 294.000 K | 215.000 K | 190.000 K | 165.000 K | 140.000 K | |
| Other Assets | 403.000 K | 484.000 K | 640.000 K | 542.000 K | 541.000 K | 4.956 M | 3.055 M | 4.318 M | |
| Intangible Assets | 0.000 | 0.000 | 14.949 M | 14.681 M | 14.413 M | 14.146 M | 13.878 M | 28.863 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 128.001 M | 115.609 M | 134.279 M | 123.612 M | 117.091 M | 115.324 M | 117.225 M | 126.519 M | |
| Total liabilities | 131.678 M | 135.443 M | 147.895 M | 147.869 M | 145.206 M | 147.158 M | 145.869 M | 158.190 M | |
| Total current liabilities | 54.955 M | 47.265 M | 65.211 M | 45.518 M | 44.023 M | 48.273 M | 53.267 M | 73.198 M | |
| Accounts Payable | 2.155 M | 2.721 M | 22.508 M | 6.295 M | 5.240 M | 7.999 M | 7.142 M | 9.276 M | |
| Other liabilities | 46.888 M | 48.710 M | 42.264 M | 42.065 M | 40.981 M | 38.760 M | 39.944 M | 39.982 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 7.229 M | 14.780 M | |
| Long term debt | 29.835 M | 39.468 M | 39.448 M | 59.484 M | 59.574 M | 59.659 M | 52.373 M | 44.910 M | |
| Other liabilities | 46.888 M | 48.710 M | 42.264 M | 42.065 M | 40.981 M | 38.760 M | 39.944 M | 39.982 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -3.677 M | -19.834 M | -13.616 M | -24.257 M | -28.115 M | -31.834 M | -28.644 M | -31.671 M | |
| Common stock | 172.147 M | 172.836 M | 172.867 M | 173.568 M | 173.748 M | 174.364 M | 174.388 M | 175.203 M | |
| Retained earnings | -1.365 B | -1.384 B | -1.382 B | -1.396 B | -1.403 B | -1.408 B | -1.408 B | -1.416 B |